Opening soonNot applicableObservational
What this study is about
The primary objectives are to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort and relevant subgroups. This study is based on anonymized electronic health record (EHR) data and spanning January 2022 to December 2025. EHR will be extracted from participants of Acibadem hospital network in Turkey. Participants received routine clinical care according to physician discretion. Index date will be defined by the first diagnosis of cardiometabolic conditions. Follow-up period will include at least one year of to allow description of long-term outcomes. It will extend until the end of study, last recorded encounter, or death.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age12 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Type 2 Diabetes (T2D), Prediabetes, Cardiovascular Disease (CVD), Dyslipidemia, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Chronic Kidney Disease (CKD)
Full registry criteria
Inclusion Criteria: * Participants aged above or equal to 12 years at index date. * Participants with international classification of diseases (ICD-10) coded diagnosis or secondary criteria for either diabetes (type 2 diabetes, pre-diabetes), overweight, obesity, metabolic dysfunction-associated steatotic liver disease (or non-alcoholic fatty liver disease), cardiovascular disease (arterial hypertension, ischemic heart disease, myocardial infarction, heart failure, cerebrovascular disease (including stroke and transient ischemic attack), atherosclerosis, atrial fibrillation), chronic kidney disease, dyslipidemia. * At least one healthcare encounter within 12 months prior to index date (pre-index) to ensure availability of baseline data. Exclusion Criteria: * None.
Primary outcomes
Index and yearly prevalence of major cardiometabolic diseases (percentage)Baseline (at index date i.e., between 1 January 2022 to 31 December 2025), and at the end of each calendar yearMeasured in percentage
Index and yearly prevalence of major cardiometabolic diseases: binary (yes/no)Baseline (at index date i.e., between 1 January 2022 to 31 December 2025), and at the end of each calendar yearMeasured as binary (yes/no)
Overlap of major cardiometabolic diseases (percentage)Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)Presence of two or more predefined cardiometabolic conditions documented on or prior to the index date. Measured as percentage
Overlap of major cardiometabolic diseases: binary (yes/no)Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)Presence of two or more predefined cardiometabolic conditions documented on or prior to the index date. Measured as binary (yes/no)
Age distributionBaseline (at index date i.e., between 1 January 2022 to 31 December 2025)Measured in years
Age distribution: Number of participantsBaseline (at index date i.e., between 1 January 2022 to 31 December 2025)Measured as number of participants
Gender distributionBaseline (at index date i.e., between 1 January 2022 to 31 December 2025)Defined as male or female. Measured in percentage
Gender distribution: binary (yes/no)Baseline (at index date i.e., between 1 January 2022 to 31 December 2025)Defined as count of male or female. Measured as binary (male/female)
